Stocktoria
Immunocore Holdings plc IMCR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-05
Immunocore Holdings plc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $400.0M | $310.2M | $249.4M | $174.4M |
| R&D expense | $274.9M | $222.2M | $163.5M | $101.9M |
| SG&A expense | $165.4M | $155.8M | $144.5M | $123.1M |
| Operating income | -$45.4M | -$70.5M | -$59.6M | -$51.7M |
| Interest expense | — | — | $5.2M | $5.4M |
| Income tax | $16.4M | -$1.9M | -$5.6M | $11.7M |
| Net income | -$35.5M | -$51.1M | -$55.3M | -$52.5M |
| EPS (diluted) | $-0.71 | $-1.02 | $-1.13 | $-1.15 |
| Operating cash flow | -$10.7M | $26.1M | $2.9M | -$49.2M |
| Free cash flow | -$15.1M | $20.9M | -$2.5M | -$51.4M |
| Cash & equivalents | $467.7M | $455.7M | $442.6M | $402.5M |
| Inventory | $6.7M | $5.4M | $4.5M | $692,000 |
| Total assets | $1.1B | $1.0B | $597.0M | $526.8M |
| Total liabilities | $686.2M | $648.8M | $228.2M | $187.9M |
| Shareholders' equity | $381.0M | $360.7M | $368.8M | $338.9M |
Source: SEC EDGAR filings · CIK 0001671927 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.